Isan Chen, MBrace Therapeutics president and CEO
November 14, 2023 08:30 AM ESTUpdated 12:42 PM
Financing
Startups

MBrace Ther­a­peu­tics cap­i­tal­izes on ADC wave with $85M Se­ries B to en­ter the clin­ic this quar­ter

Kyle LaHucik

Senior Reporter

MBrace Ther­a­peu­tics has raised an $85 mil­lion Se­ries B for a Phase I clin­i­cal tri­al of its first an­ti­body-drug con­ju­gate as in­vestors and Big Phar­mas …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Evotec gains on Halozyme's takeover pro­pos­al

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times